Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response

International Journal of Cancer

Volumn 66, Issue 1, 1996, Pages 135-139

  Gunji, Yoshio ^a   Tagawa, Masatoshi ^a   Matsubara, Hisahiro ^a   Takenaga, Keizo ^b   Shimada, Hideaki ^a   Kondo, Fukuo ^a   Suzuki, Takao ^a   Nakajima, Kazuaki ^a   Aoki, Taito ^a   Asano, Takehide ^a   Ochiai, Takenori ^a   Isono, Kaichi ^a   Kageyama, Hajime ^b   Nakamura, Yohko ^b   Sakiyama, Shigeru ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CARCINOGENICITY; COLON CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; GENETIC TRANSDUCTION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; COLONIC NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TRANSFECTION;

EID: 9244258537     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960328)66:1<135::AID-IJC23>3.0.CO;2-B     Document Type: Conference Paper

References (27)

1. ARIENTI, F., SULÉ-SUSO, J., MELANI, C., MACCALLI, C., BELLI, F., ILLENI, M.T., ANICHINI, A., CASCINELLI, N., COLOMBO, M.P. and PARMIANI, G., Interleukin-2 gene transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum. Gene Ther., 5, 1139-1150 (1994).
2. BELLDEGRUN, A., TSO, C.-L., SAKATA, T., DUCKETT, T., BRUNDA, M.J., BARSKY, S.H., CHAI, J., KABOO, R., LAVEY, R.S., MCBRIDE, W.H. and DEKERNION, J B., Human renal carcinoma line transfected with interleukin-2 and/or interferon α gene(s): implications for live cancer vaccines. J. nat. Cancer Inst., 85, 207-216 (1993).
3. BRATTAIN, M.G., STROBEL-STEVENS, J., FINE, D., WEBB, M. and SARRIF, A.M., Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res., 40, 2142-2146 (1980).
4. CIGNETTI, A., GLARINI, A., CARBONE, A., FORNI, M., CRONIN, K., FORNI, G., GANSBACHER, B. and FOA, R., Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J. nat. Cancer Inst., 86, 785-791 (1994).
5. COLOMBO, M.P., FERRARI, G., STOPPACCIARO, A., PARENZA, M., RODOLFO, M., MAVILIO, F. and PARMIANI, G., Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. exp. Med., 173, 889-897 (1991).
6. CORBETT, T.H., GRISWOLD, D.P., JR., ROBERTS, B.J., PECKHAM, J.C. and SCHABEL, F.M., JR., Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays. with a note on carcinogen structure. Cancer Res., 35, 2434-2439 (1975).
7. FAKHRAI, H., SHAWLER, D.L., GJERSET, R., NAVIAUX, R.K., KOZIOL, J., ROYSTON, I. and SOBOL, R.E., Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther., 6, 591-601 (1995).
8. FEARON, E.R., PARDOLL, D.M., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.I., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B. and FROST, P., Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60, 397-403 (1990).
9. GANSBACHER, B., ZIER, K., CRONIN, K., HANTZOPOULOS, P.A., BOUCHARD, B., HOUGHTON, A., GILBOA, E. and GOLDE, D., Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood, 80, 2817-2825 (1992).
10. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R. and GILBOA, E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. exp. Med., 172, 1217-1224 (1990).
11. GASTL, G., FINSTAD, C.L., GLARINI, A., BOSL, G., GILBOA, E., BANDER, N.H. and GANSBACHER, B., Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res , 52, 6229-6236 (1992).
12. HADDADA, H., RAGOT, T., CORDIER, L., DUFFOUR, M.T. and PERRICAUDET, M., Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum. Gene Ther., 4, 703-711 (1993).
13. JANIK, P., BRIAND, P. and HARTMANN, N.R., The effect of estroneprogesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res., 35, 3698-3704 (1975).
14. KARP, S.E., FARBER, A., SALO, J.C., HWU, P., JAFFE, G., ASHER, A.L., SHILONI, E., RESTIFO, N.P., MULÉ, J.J. and ROSENBERG, S.A., Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: tumor inhibition by IL-2 but not tumor necrosis factor. J. Immunol., 150, 896-908 (1993).
15. + lymphocytes during virus infection in vivo. J. Immunol., 142, 1287-1292 (1989).
16. MATTIJSSEN, V., DE MULDER, P.M., SCHORNAGEL, J.H., VERWEIJ, J., VAN DEN BROEK, P., GALAZKA, A., ROY, S. and RUITER, D.J., Clinical and immunopathological results of phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, non pretreated head and neck squamous cell carcinoma. J. Immunother., 10, 63-68 (1991).
17. MILLER, A.D., Human gene therapy comes of age. Nature (Lond.), 357, 455-460 (1992).
18. MILLER, A.D. and ROSMAN, G.J., Improved retroviral vectors for gene transfer and expression. BioTechniques, 7, 980-990 (1989).
19. ROBERTSON, M.J. and RITZ, J., Biology and clinical relevance of human natural killer cells. Blood, 76, 2421-2438 (1990).
20. ROSENTHAL, P.M., CRONIN, K., BANNERJI, R., GOLDE, D.W. and GANSBACHER, B., Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood, 83, 1289-1298 (1994).
21. SAITO, S., BANNERJI, R., GANSBACHER, B., ROSENTHAL, F M., ROMANENKO, P., HESTON, W.D., FAIR, W.R. and GILBOA, E., Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccine. Cancer Res., 54, 3516-3520 (1994).
22. SCHMIDT, W., SCHWEIGHOFFER, T., HERBST, E., MAASS, G., BERGER, M , SCHILCHER, F., SCHAFFNER, G. and BIRNSTIEL, M., Cancer vaccines. the interleukin 2 dosage effect. Proc. nat. Acad. Sci. (Wash.), 92, 4711-4714 (1995).
23. SOBOL, R.E. and SCANLON, K.J., Cancer gene therapy clinical trials. Cancer Gene Ther., 2, 5-6 (1995).
24. TEPPER, R.I. and MULÉ, J.J., Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther., 5, 153-164 (1994).
25. TRINCHIERI, G., Biology of natural killer cells. Adv. Immunol. 47, 187-379 (1989).
26. TSAI, S.-C.J., GANSBACHER, B., TAIT, L., MILLER, F.R. and HEPPNER, G.H., Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. nat. Cancer Inst., 85, 546-553 (1993).
27. YAMADA, G., KITAMURA, Y., SONODA, H., HARADA, H., TAKI, S., MULLIGAN, R.C., OSAWA, H., DIAMANTSTEIN, T., YOKOYAMA, S. and TANIGUCHI, T., Retrovial expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J., 6, 2705-2709 (1987).